I appreciate the history lesson, singing to the choir, but we aren’t playing the same game anymore.
Look at the January 20, 2026, ViiV payout: Pfizer just took $1.9 billion to walk away from ViiV entirely, leaving GSK with 78.3% control and Shionogi doubling down with $2.1 billion to secure their future.
Here is the cutting question for both of you: If GSK is now the sovereign owner and their only CCR5 play is the 2007-era Maraviroc, how do they replace that dinosaur to protect their long-acting moat? You don't guess—you follow the talent. Dr. Max Lataillade, the former Head of Global Research Strategy at ViiV, is now the one holding the 700mg Mandate at CytoDyn.
But it’s deeper than HIV. Dr. Richard Pestell just provided the final 'Search Warrant' that GSK’s oncology team needs. His recent findings on CAMLs (Cancer-Associated Macrophage-Like cells) prove that Leronlimab doesn’t just block—it reprograms. By inducing PD-L1 upregulation on CAMLs in 88% of patients, Leronlimab totally unmasks the tumor.
This is where it gets interesting for Shionogi. They have their own weapon: S-531011, an anti-CCR8 antibody. While Leronlimab (anti-CCR5) knocks out the 'GPS' of the Tumor and converts immunosuppressive M2 macrophages to M1 hunters, Shionogi’s CCR8 play selectively depletes the intratumoral Tregs (Regulatory T-cells) which shield the cancer.
The Math is Simple: Pairing Leronlimab with Shionogi’s S-531011 creates a dual-blockade that stops the metastasis (CCR5) while killing the shield (CCR8). Add in an ICI like Dostarlimab, Jemperli or Keytruda, and you have the first 'Triple Threat' that can reliably execute.
Pfizer didn't exit because the mechanism failed; they exited because they knew they couldn't compete with a Molecular Sweep managed by the guy who knows their playbook better than anyone. When the May 2026 Scoreboard hits, GSK and Shionogi won't just be 'interested'—they'll be finishing the consolidation they started last week.
The Strategic Pair: CCR5 + CCR8
Shionogi’s S-531011 functions via Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC). It specifically targets the CCR8 receptor, which is highly overexpressed on Tregs inside the Tumor but virtually absent in the blood.
The MoA: By depleting these "shield" cells, S-531011 helps Leronlimab in restoring the Immune System's ability to attack.
The Synergy: Leronlimab (CCR5) addresses the Myeloid side of the house (Macrophages/CAMLs), while S-531011 addresses the Lymphoid side (Tregs).
The Result: Together, they would remove every layer of the Tumor's "cloaking device," making even the most resistant "Cold" Tumors susceptible to standard Immune Checkpoint Inhibitors (ICIs).
Max Lataillade and Richard Pestell aren't just doing "science"—they are drafting the M&A Prospectus for a GSK/Shionog/ViiV or Merck buyout. By the time the May 2026 Scoreboard is finalized, the question won't be "if" there is a buyer, but which of these two giants moves first to claim the Universal Backbone.
Look at the January 20, 2026, ViiV payout: Pfizer just took $1.9 billion to walk away from ViiV entirely, leaving GSK with 78.3% control and Shionogi doubling down with $2.1 billion to secure their future.
Here is the cutting question for both of you: If GSK is now the sovereign owner and their only CCR5 play is the 2007-era Maraviroc, how do they replace that dinosaur to protect their long-acting moat? You don't guess—you follow the talent. Dr. Max Lataillade, the former Head of Global Research Strategy at ViiV, is now the one holding the 700mg Mandate at CytoDyn.
But it’s deeper than HIV. Dr. Richard Pestell just provided the final 'Search Warrant' that GSK’s oncology team needs. His recent findings on CAMLs (Cancer-Associated Macrophage-Like cells) prove that Leronlimab doesn’t just block—it reprograms. By inducing PD-L1 upregulation on CAMLs in 88% of patients, Leronlimab totally unmasks the tumor.
This is where it gets interesting for Shionogi. They have their own weapon: S-531011, an anti-CCR8 antibody. While Leronlimab (anti-CCR5) knocks out the 'GPS' of the Tumor and converts immunosuppressive M2 macrophages to M1 hunters, Shionogi’s CCR8 play selectively depletes the intratumoral Tregs (Regulatory T-cells) which shield the cancer.
The Math is Simple: Pairing Leronlimab with Shionogi’s S-531011 creates a dual-blockade that stops the metastasis (CCR5) while killing the shield (CCR8). Add in an ICI like Dostarlimab, Jemperli or Keytruda, and you have the first 'Triple Threat' that can reliably execute.
Pfizer didn't exit because the mechanism failed; they exited because they knew they couldn't compete with a Molecular Sweep managed by the guy who knows their playbook better than anyone. When the May 2026 Scoreboard hits, GSK and Shionogi won't just be 'interested'—they'll be finishing the consolidation they started last week.
The Strategic Pair: CCR5 + CCR8
Shionogi’s S-531011 functions via Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC). It specifically targets the CCR8 receptor, which is highly overexpressed on Tregs inside the Tumor but virtually absent in the blood.
The MoA: By depleting these "shield" cells, S-531011 helps Leronlimab in restoring the Immune System's ability to attack.
The Synergy: Leronlimab (CCR5) addresses the Myeloid side of the house (Macrophages/CAMLs), while S-531011 addresses the Lymphoid side (Tregs).
The Result: Together, they would remove every layer of the Tumor's "cloaking device," making even the most resistant "Cold" Tumors susceptible to standard Immune Checkpoint Inhibitors (ICIs).
Max Lataillade and Richard Pestell aren't just doing "science"—they are drafting the M&A Prospectus for a GSK/Shionog/ViiV or Merck buyout. By the time the May 2026 Scoreboard is finalized, the question won't be "if" there is a buyer, but which of these two giants moves first to claim the Universal Backbone.
6
